REGN
NASD Regeneron Pharmaceuticals, Inc.$733.81 ↓ -1.39 (-0.19%) Trading Down from the previous close of $735.20
- YTD change
- -4.93%
- vs 20-day SMA
- -6.26%
- vs 200-day SMA
- -0.30%
Price ranges
Price & Performance
-27.84 (-3.65%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 39.4% away from all-time highs of $1,211.20
- REGN is down 5% since the beginning of the year
- REGN is up 22% over the past 12 months
- REGN is down 13% over the past 1 month
- 3% of all REGN investors are betting against REGN
REGN reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is +25.6%.
- Previous minute
- +$0.00
- Last hour
- -$1.41
- Last 5 days
- -6.88%
- vs 8-day SMA
- -4.03%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
